SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Patrick M Reagan, Jonathan W Friedberg, Brentuximab vedotin for the treatment of Hodgkin’s and non-Hodgkin’s lymphoma, Expert Opinion on Orphan Drugs, 2015, 3, 5, 609

    CrossRef

  2. 2
    Heidys Garrote, Adolfo de la Fuente, Raquel Oña, Inmaculada Rodríguez, Juan E Echevarría, Juan M Sepúlveda, Juan F García, Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia, Experimental Hematology & Oncology, 2015, 4, 1, 8

    CrossRef

  3. 3
    Francesca Rossi, Scott D. Newsome, Raphael Viscidi, Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients, Molecular and Cellular Probes, 2015, 29, 1, 54

    CrossRef

  4. 4
    Jaffar A. Al-Tawfiq, Ramzi W. Banda, Riyadh A. Daabil, M. Fawaz Dawamneh, Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: A case report and literature review, Journal of Infection and Public Health, 2015,

    CrossRef

  5. 5
    Jennifer A. DeSimone, Pooja Sodha, Desislava Ignatova, Reinhard Dummer, Antonio Cozzio, Emmanuella Guenova, Recent advances in primary cutaneous T-cell lymphoma, Current Opinion in Oncology, 2015, 27, 2, 128

    CrossRef

  6. 6
    Brentuximab vedotin, Reactions Weekly, 2014, 1517, 1, 46

    CrossRef

  7. 7
    Delia Dima, Ciprian Tomuleasa, Alexandru Irimie, Ioan-Stefan Florian, Bobe Petrushev, Ioana Berindan-Neagoe, Andrei Cucuianu, Magnetic resonance imaging-based diagnosis of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma after therapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab, Cancer, 2014, 120, 24